Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL375890 | 0.91 | PDE4B (0.43) | HSD17B10PDE4BEPHX1HPGDGPR119 | |
| SCHEMBL6992304 | 0.85 | HSD17B10 (0.47) | HSD17B10NR1H2NR1H3SMN1; SMN2NPC1 | |
| SCHEMBL9937434 | 0.83 | CHRM2 (0.37) | EPHX1 | |
| SCHEMBL9965340 | 0.83 | PARP1 (0.53) | KLK7SMN1; SMN2NPC1PDE4B | |
| SCHEMBL28003378 | 0.83 | PARP1 (0.53) | KLK7SMN1; SMN2NPC1PDE4B | |
| SCHEMBL28003380 | 0.82 | HSD17B10 (0.51) | HSD17B10KLK7SMN1; SMN2NPC1EPHX2 | |
| SCHEMBL28060561 | 0.82 | NR1H2 (0.53) | HSD17B10NR1H2NR1H3SMN1; SMN2NPC1 | |
| SCHEMBL29695403 | 0.82 | HSD17B10 (0.50) | HSD17B10NR1H2NR1H3SMN1; SMN2NPC1 | |
| SCHEMBL13604577 | 0.81 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2PDE4BEPHX1HPGD | |
| SCHEMBL5253414 | 0.81 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2PDE4BEPHX1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2864318-B1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1R KINASE INHIBITORS | MACROPHAGE PHARMA LTD (GB) | 2017-08-09 | — | — | EP | disclosed |
| US-20170157118-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | MACROPHAGE PHARMA LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| US-9604940-B2 | 2-aminopyrazine derivatives as CSF-1R kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2017-03-28 | — | — | US | disclosed |
| US-20150368210-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2015-12-24 | — | — | US | disclosed |
| US-20140010762-A1 | IMAGING AGENTS | CHROMA THERAPEUTICS LTD (GB) | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157118-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | CSF1R, CSF3R, FLT3 | HSD17B10 4299/4885KLK7 1728/4885NR1H2 2067/4885 |
| US-20140010762-A1 | IMAGING AGENTS | CES1, CES2, NCEH1 | HSD17B10 34/4885KLK7 3149/4885NR1H2 938/4885 |
| US-20150368210-A1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1 R KINASE INHIBITORS | CSF1R, CSF3R, FLT3 | HSD17B10 4299/4885KLK7 1728/4885NR1H2 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.